Genomic Health Company Profile (NASDAQ:GHDX)

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GHDX
  • CUSIP: 37244C10
  • Web:
  • Market Cap: $1.1731 billion
  • Outstanding Shares: 34,645,000
Average Prices:
  • 50 Day Moving Avg: $31.98
  • 200 Day Moving Avg: $31.72
  • 52 Week Range: $26.37 - $34.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 93.67
  • P/E Growth: -152.55
Sales & Book Value:
  • Annual Revenue: $334.47 million
  • Price / Sales: 3.49
  • Book Value: $4.91 per share
  • Price / Book: 6.87
  • EBITDA: $2.61 million
  • Net Margins: -1.50%
  • Return on Equity: -4.33%
  • Return on Assets: -3.39%
  • Current Ratio: 3.95%
  • Quick Ratio: 3.95%
  • Average Volume: 113,040 shs.
  • Beta: 0.77
  • Short Ratio: 11.25

Frequently Asked Questions for Genomic Health (NASDAQ:GHDX)

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) released its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.02. The firm earned $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company's revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) EPS. View Genomic Health's Earnings History.

When will Genomic Health make its next earnings announcement?

Genomic Health is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Genomic Health.

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

7 brokers have issued 12 month target prices for Genomic Health's stock. Their predictions range from $27.00 to $35.00. On average, they expect Genomic Health's stock price to reach $31.83 in the next year. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:

  • Kimberly J. Popovits, Chairman of the Board, President, Chief Executive Officer
  • Gordon Bradley Cole, Chief Financial Officer, Chief Operating Officer
  • Steven Shak M.D., Chief Scientific Officer
  • Phillip Febbo M.D., Chief Medical Officer
  • Laura Leber Kammeyer, Chief Communications Officer
  • Frederic Pla Ph.D., Chief Business and Product Development Officer
  • James Vaughn, Chief Commercial Officer
  • Julian C. Baker, Lead Independent Director
  • Felix J. Baker Ph.D., Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of Genomic Health stock can currently be purchased for approximately $33.72.

MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)
Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $31.83 (5.60% downside)
Consensus Price Target History for Genomic Health (NASDAQ:GHDX)
Price Target History for Genomic Health (NASDAQ:GHDX)
Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/27/2017Canaccord GenuityReiterated RatingBuy$35.00 -> $35.00LowView Rating Details
9/14/2017Jefferies Group LLCReiterated RatingHold$33.00LowView Rating Details
9/1/2017Cowen and CompanyReiterated RatingHold$34.00LowView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$31.00LowView Rating Details
5/3/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$31.00N/AView Rating Details
1/9/2017Barclays PLCReiterated RatingSell$27.00N/AView Rating Details
8/3/2016Bank of America CorporationSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Genomic Health (NASDAQ:GHDX)
Earnings by Quarter for Genomic Health (NASDAQ:GHDX)
Earnings History by Quarter for Genomic Health (NASDAQ GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.01N/AView Earnings Details
8/1/2017Q2 2017($0.06)($0.08)$86.08 million$85.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Genomic Health (NASDAQ:GHDX)
2017 EPS Consensus Estimate: $0.00
2018 EPS Consensus Estimate: $0.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.08)$0.02($0.03)
Q2 20172($0.07)($0.07)($0.07)
Q3 20172($0.01)$0.02$0.01
Q4 20172$0.08$0.11$0.10
Q1 20181$0.07$0.07$0.07
Q2 20181$0.07$0.07$0.07
Q3 20181$0.07$0.07$0.07
Q4 20181$0.07$0.07$0.07
(Data provided by Zacks Investment Research)


Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Genomic Health (NASDAQ:GHDX)
Insider Ownership Percentage: 46.20%
Institutional Ownership Percentage: 88.90%
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017G Bradley ColeCOOSell5,000$31.93$159,650.00View SEC Filing  
9/14/2017Kimberly J. PopovitsInsiderSell5,000$31.00$155,000.00View SEC Filing  
9/12/2017G Bradley ColeCOOSell5,000$31.86$159,300.00View SEC Filing  
8/14/2017Kimberly J. PopovitsInsiderSell5,000$30.22$151,100.00View SEC Filing  
8/8/2017G Bradley ColeCOOSell5,000$30.57$152,850.00View SEC Filing  
8/8/2017James J. VaughnInsiderSell8,000$30.59$244,720.00View SEC Filing  
7/19/2017Phillip G. FebboInsiderSell3,174$33.57$106,551.18View SEC Filing  
7/11/2017G Bradley ColeCOOSell5,000$32.53$162,650.00View SEC Filing  
7/5/2017Kimberly J. PopovitsInsiderSell5,000$32.59$162,950.00View SEC Filing  
7/5/2017Kimberly J. PopovitsCEOSell1,468$32.67$47,959.56View SEC Filing  
6/23/2017Steven ShakInsiderSell5,000$33.27$166,350.00View SEC Filing  
6/5/2017Kimberly J. PopovitsInsiderSell5,000$32.32$161,600.00View SEC Filing  
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.00View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.00View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.00View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Genomic Health (NASDAQ:GHDX)
Latest Headlines for Genomic Health (NASDAQ:GHDX)
DateHeadline logoGenomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $87.06 Million - October 21 at 2:54 PM logoFinancial Analysis: Genomic Health (GHDX) & Its Peers - October 17 at 2:08 PM logoGenomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from Brokerages - October 15 at 4:46 AM logoGenomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment Research - October 13 at 1:54 PM logoGenomic Health, Inc. (GHDX) COO Sells $159,650.00 in Stock - October 11 at 7:50 PM logoZacks Investment Research Lowers Genomic Health, Inc. (GHDX) to Sell - October 8 at 7:20 PM logoGenomic Health's Cost Pressure Mounts, Cancer Tests Strong - October 5 at 11:45 PM logoGenomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord Genuity - October 1 at 5:14 PM logoContrasting Genomic Health (GHDX) & Inovio Pharmaceuticals (INO) - September 28 at 10:50 PM logoGenomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017 - September 27 at 8:34 AM logoETFs with exposure to Genomic Health, Inc. : September 26, 2017 - September 26 at 6:50 PM logoGenomic Health, Inc. (GHDX) Given Consensus Rating of "Hold" by Analysts - September 20 at 4:44 AM logoGenomic Health, Inc. (GHDX) Insider Kimberly J. Popovits Sells 5,000 Shares - September 18 at 4:18 PM logoInsider Selling: Genomic Health, Inc. (GHDX) COO Sells 5,000 Shares of Stock - September 14 at 11:36 PM logoETFs with exposure to Genomic Health, Inc. : September 14, 2017 - September 14 at 7:39 PM logoGenomic Health, Inc. (GHDX) Earns "Hold" Rating from Jefferies Group LLC - September 14 at 7:16 PM logoGenomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 14 at 2:52 AM logoGenomic Health teams up with Biocartis to develop IVD version of Oncotype DX breast cancer test - September 13 at 7:52 AM logoGenomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access - September 13 at 5:54 AM logoBiocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access - September 13 at 1:27 AM logoGHDX Crosses Above Average Analyst Target - September 12 at 7:50 PM logoGenomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017 - September 11 at 7:32 PM logoGenomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 5, 2017 - September 6 at 1:12 AM logoGenomic Health, Inc. (GHDX) Given "Hold" Rating at Cowen and Company - September 4 at 9:26 PM logoGenomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress - August 31 at 6:57 PM logoGHDX Crosses Above Key Moving Average Level - August 30 at 5:37 AM logoGenomic Health, Inc. (GHDX) Receives Consensus Rating of "Hold" from Brokerages - August 26 at 4:34 AM logoGenomic Health (GHDX) Says Medicare Establishes Final Local Coverage Determination (LCD) for Use of Oncotype DX GPS Test - August 25 at 6:02 AM logoMedicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017 - August 25 at 6:02 AM logoKimberly J. Popovits Sells 5,000 Shares of Genomic Health, Inc. (GHDX) Stock - August 16 at 10:44 PM logoCanaccord Genuity Lowers Genomic Health, Inc. (GHDX) Price Target to $35.00 - August 15 at 3:38 PM logoGenomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : August 12, 2017 - August 12 at 12:30 AM logoInsider Selling: Genomic Health, Inc. (NASDAQ:GHDX) COO Sells 5,000 Shares of Stock - August 9 at 10:22 PM logoGenomic Health, Inc. (NASDAQ:GHDX) Insider Sells $244,720.00 in Stock - August 9 at 10:20 PM logoGenomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $89.44 Million - August 7 at 8:32 AM logoGenomic Health, Inc. (GHDX) Earns Hold Rating from Piper Jaffray Companies - August 3 at 1:42 PM logoGenomic Health, Inc.: Still Waiting for Reimbursement - August 3 at 10:03 AM logoBrokers Issue Forecasts for Genomic Health, Inc.'s Q3 2017 Earnings (GHDX) - August 3 at 8:28 AM logoGenomic Health (GHDX) Shares Cross Below 200 DMA - August 2 at 8:35 PM logoGenomic Health (GHDX) Posts Wider-than-Expected Loss in Q2 - August 2 at 3:20 PM logoEdited Transcript of GHDX earnings conference call or presentation 1-Aug-17 8:30pm GMT - August 2 at 5:42 AM logoGenomic Health, Inc. (GHDX) Issues Quarterly Earnings Results - August 1 at 10:30 PM logoGenomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress - August 1 at 7:37 PM logoGenomic Health reports 2Q loss - August 1 at 7:37 PM logoGenomic Health, Inc. (NASDAQ:GHDX) Given Average Recommendation of "Hold" by Analysts - August 1 at 8:04 AM logoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : July 28, 2017 - July 28 at 9:30 PM logoInsider Selling: Genomic Health, Inc. (NASDAQ:GHDX) Insider Sells 3,174 Shares of Stock - July 21 at 7:50 PM logoGenomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017 - July 20 at 4:49 PM logoG Bradley Cole Sells 5,000 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock - July 13 at 8:16 PM logoUpdated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer - July 12 at 7:44 PM



Genomic Health (GHDX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.